Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gold-198 is a radioactive isotope of the element gold used primarily as a radiopharmaceutical for cancer therapy and diagnostic imaging. It emits beta radiation with a half-life of approximately 2.7 days. In medicine, it is most commonly administered as colloidal suspensions or in seed form for brachytherapy—an internal radiotherapy technique where the radioactive source is placed directly into or near tumor tissue to deliver localized irradiation while minimizing exposure to surrounding healthy tissues. Gold Au‑198 has been used in the treatment of various cancers including prostate cancer (as permanent seed implants), bladder tumors (via intracavitary instillation), and other malignancies; it has also served as a diagnostic aid in liver imaging and to estimate hepatic blood flow. Its mechanism of action relies on delivering cytotoxic ionizing radiation locally to induce cell death within malignant tissues[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gold-198.